NSB — Neuroscientific Biopharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00- AU$5.21m
- AU$0.25m
- AU$2.39m
- 51
- 70
- 20
- 47
Annual balance sheet for Neuroscientific Biopharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 3.29 | 14.2 | 7.22 | 4.91 | 4.95 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.019 | 0.049 | 0.121 | 0.043 | 0.054 |
| Prepaid Expenses | |||||
| Total Current Assets | 3.31 | 14.4 | 7.4 | 5.01 | 5.04 |
| Net Property, Plant And Equipment | 0.009 | 0.028 | 0.017 | 0.009 | 0.006 |
| Net Intangible Assets | |||||
| Total Assets | 3.74 | 14.8 | 7.74 | 5.29 | 5.44 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.089 | 0.223 | 2.22 | 0.597 | 0.086 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.089 | 0.223 | 2.22 | 0.597 | 0.086 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 3.65 | 14.6 | 5.52 | 4.69 | 5.35 |
| Total Liabilities & Shareholders' Equity | 3.74 | 14.8 | 7.74 | 5.29 | 5.44 |
| Total Common Shares Outstanding |